Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Authors:
- Aharona Glatman-FreedmanAGAharona Glatman-Freedman
- Michal BrombergMBMichal Bromberg
- Yael HershkovitzYHYael Hershkovitz
- Hanna SeftyHSHanna Sefty
- Zalman KaufmanZKZalman Kaufman
- Rita DichtiarRDRita Dichtiar
- Lital Keinan-BokerLKLital Keinan-Boker
Open Access
- 1 May 2022
- journal article
- research article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 28 (5) , 948-956
Abstract
Effectiveness of BNT162b2 BoosterKeywords
This publication has 12 references indexed in Scilit:
- Effectiveness of BNT162b2 Vaccine against Omicron Variant in South AfricaNew England Journal of Medicine, 2021
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsNew England Journal of Medicine, 2021
- Protection against Covid-19 by BNT162b2 Booster across Age GroupsNew England Journal of Medicine, 2021
- Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021Emerging Infectious Diseases, 2021
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational studyThe Lancet, 2021
- Waning Immunity after the BNT162b2 Vaccine in IsraelNew England Journal of Medicine, 2021
- Protection of BNT162b2 Vaccine Booster against Covid-19 in IsraelNew England Journal of Medicine, 2021
- Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare WorkersVaccines, 2021
- The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised dataEBioMedicine, 2021
- Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort StudySSRN Electronic Journal, 2021